ReviewCancers2023

Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis.

Cristina Bezzio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.